Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 3 3Phase NA 1Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 3Breast Neoplasms 3Esophageal Squamous Cell Carcinoma 2Colonic Neoplasms 2Carcinoma, Hepatocellular 2Recurrence 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oesophagogastric Cancer 1Neoplasms 1Inflammatory Breast Neoplasms 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Gemcitabine 16Fluorouracil 6Irinotecan 4Cisplatin 4Capecitabine 4Oxaliplatin 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3nimotuzumab 2Taxes 2Phytotherapy 2Leucovorin 2Drug Therapy 2surufatinib 1rubitecan 1racemetyrosine 1pertuzumab 1pembrolizumab 1methylnaltrexone 1folfirinox 1cyclopropapyrroloindole 1camrelizumab 1Trastuzumab 1Tranexamic Acid 1Standard of Care 1Sirolimus 1Radiotherapy 1Positron Emission Tomography Computed Tomography 1Phenytoin 1Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Pancreatic Neoplasms × Neoadjuvant Therapy × Clear all
NCT01458717 2018-05-02

Neoadjuvant Chemoradiation in Patients With Borderline Resectable Pancreatic Cancer

Seoul National University Hospital

Phase 2/3 Completed
58 enrolled
Gastrointestinal

Neoplasms, Pancreatic Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡